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Alternative Therapies for Treatment of Keratoconjunctivitis Sicca Associated with
Sjogren's Syndrome
Abstract
Background: Sjogren’s syndrome is a chronic, systemic autoimmune disorder, which often results in
significant ocular surface disease. Dry eye associated with Sjogren’s syndrome is a multifactorial disease
which leads to decreased function of the lacrimal glands and altered tear composition. There currently
are numerous anti-inflammatory methods used for treatment of this disease.
Case Report: This case report will focus on the use of amniotic membrane placement and autologous
serum tears to facilitate a successful scleral contact lens fit allowing for reduced ocular inflammation and
discomfort associated with Keratoconjunctivitis sicca due to Sjogren’s syndrome.
Conclusion: Clinical management of keratoconjunctivitis sicca due to Sjogren’s syndrome can be
challenging. Diagnosis often requires numerous in office testing including Schirmer I/II, TBUT, sodium
fluorescein stain, and osmolarity. Such testing can be repeated over time to monitor for improvement with
addition of each new therapy. Various treatment modalities such as topical lubricants, cyclosporine,
autologous serum tears, or amniotic membranes have been proven to provide short-term benefits and
excellent maintenance of symptoms. Utilizing such treatments to promote an ideal scleral contact lens fit
provides lasting benefits of corneal clarity and stable vision.
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INTRODUCTION
Keratoconjunctivitis sicca (KCS) is an ocular surface disease, first described by
Henrik Sjogren, and is characterized by inflammation resulting in corneal and
conjunctival staining.1,2 The term KCS is used synonymously with dry eye
syndrome (DES).2 In the past, two distinct etiologies of DES were described as
aqueous-deficient and evaporative.2Aqueous-deficient DES was further
distinguished as Sjogren’s Syndrome (SS) dry eye or non-SS dry eye.2 The new
classification scheme of DES acknowledges that aqueous-deficient and evaporative
DES are not mutually exclusive, but that there is overlap due to the cyclical nature
of inflammation, tear film instability and hyperosmolarity in DES.3 In particular,
SS dry eye, which had traditionally been categorized as strictly aqueous-deficient
DES, may have an evaporative component due to associated meibomian gland
dysfunction (MGD).3–5
Therefore, clinical management of KCS caused by SS, a chronic inflammatory
autoimmune disease, can be challenging. Roughly 40% of SS occurs in isolation
and is considered primary SS, while approximately 60% occurs concurrently with
another rheumatic disease and is considered secondary SS.6 Altered tear
composition due to lacrimal gland infiltration in SS leads to ocular surface
inflammation and epithelial disruption with resultant discomfort and blurred
vision.6,7 The clinical presentation of KCS secondary to SS is quite variable but
managing inflammation while re-establishing the natural tear balance on the ocular
surface is essential for the successful treatment of this condition.
CASE REPORT
A 78-year-old Caucasian female presented for examination with complaints of a
“stabbing pain” in the temporal corner OS with associated redness and crusting for
five days. She was previously diagnosed with KCS OU due to secondary SS by
another clinician. This diagnosis was made due to low Schirmer I test and a
systemic history of SS and scleroderma. The patient was currently adherent with
the following regimen to treat her condition: cyclosporine 0.05% ophthalmic
solution BID OU, preservative-free artificial tears eight times per day OU, and
0.02% hypochlorous acid lid spray QD OU. Additionally, she noted previously
unsuccessful use of punctual plugs OU (unknown timeline), as well as amniotic
membrane placement OS 2 months ago, which provided initial improvement in
corneal clarity but no long-term benefits. In addition to KCS OU, her ocular history
was significant for bilateral pseudophakia, mild normal tension glaucoma OU
(monitored without treatment), operculated retinal hole OD, and MGD OU. She
reported a surgical history of LASIK OU 19 years prior (monovision: OD corrected
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for near and OS corrected for distance), cataract surgery OU 7 years ago with toric
IOL OD and monofocal IOL OS (monovision: OD corrected for near and OS
corrected for distance), LipiFlow® (Johnson & Johnson Vision Science; New
Brunswick, New Jersey) thermal pulsation treatment OU 1 year ago, and an
appendectomy 57 years ago. The patient’s medical history was positive for
gastroesophageal reflux disease, scleroderma, and SS. Her systemic medications
included esomeprazole 22.3mg, fish oil, and folic acid, as well as the combination
of amlodipine 2.5mg and pilocarpine hydrochloride 5mg for management of her
scleroderma and SS.
The patient was oriented to person, place, and time and was of normal affect.
Uncorrected distance visual acuity was 20/70-1 OD and 20/40-2 OS. Distance
pinhole visual acuity was 20/40-1 OD and 20/25-1 OS, with an uncorrected near
vision of 20/20-2 OD. Pupils were equal, round, and reactive to light and there was
no relative afferent pupillary defect (RAPD) noted. Slit lamp biomicroscopy
revealed moderate meibomian gland dysfunction (MGD), telangiectasia, and trace
scurf OU. The tear film showed debris and an instantaneous tear break up time
(TBUT) OU. The conjunctiva revealed 2+ superior and temporal injection OU. The
right cornea showed 2+ inferior punctate epithelial erosions (PEE) with positive
sodium fluorescein staining. The left cornea showed diffuse coalesced PEE central
and inferior with positive sodium fluorescein staining, diffuse endothelial pigment,
and mucus debris. Anterior segment examination was otherwise unremarkable and
no lagophthalmos was noted with the Korb-Bkackie lid light test OU.
Due to the cornea and eyelid appearance along with the current multiple-therapy
treatment regimen, the patient was diagnosed with punctate keratitis OU (OS worse
than OD), MGD OU, and KCS due to secondary SS OU. The patient was directed
to continue current medications: cyclosporine 0.05% ophthalmic solution BID OU,
preservative-free artificial tears eight times per day OU, and 0.02% hypochlorous
acid lid spray QD OU. She was additionally started on autologous serum (AS) tears
50% every two hours OU. InSight (Metro Optics; Austin, Texas) scleral contact
lenses were ordered empirically for a future fitting with the goal of improving the
ocular surface appearance.
FOLLOW UP #1
The patient returned one month later for a dry eye evaluation. She reported good
compliance with the recommended treatment stating a subjective improvement in
ocular comfort with mild to moderate fluctuations in vision, OS worse than OD.
Uncorrected distance visual acuity was 20/60+1 OD and 20/40+1 OS with distance
pinhole visual acuity of 20/30-2 OD and 20/30-2 OS. Pupils were equal, round, and
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reactive to light, with no RAPD noted. Slit lamp biomicroscopy revealed similar
findings to the previous exam: moderate MGD, telangiectasia, and trace scurf OU
with slightly improved hyperemia along the eyelid margin OS. The tear film,
conjunctiva, and cornea showed no improvement OU.
Given the stable eyelid appearance and persistent central PEE OS causing reduced
vision in her distance monovision eye, treatment with an amniotic membrane OS
was recommended. An amniotic membrane was applied OS without complications
and a -2.50 D sphere Biofinity® (CooperVision; Lake Forest, California) soft
contact lens was inserted in the right eye to correct for distance. The patient was
directed to discontinue all topical medications OS and continue cyclosporine 0.05%
ophthalmic solution BID OD and preservative-free artificial tears as needed OD.
FOLLOW UP # 2
The patient returned three days later for evaluation post amniotic membrane
application OS. She noted significant improvement in both comfort and vision OS
and was satisfied with the distance vision OD provided by the soft contact lens.
Corrected distance visual acuity OD was 20/20 and uncorrected distance visual
acuity OS was 20/40+2, with distance pinhole acuity OS of 20/30-2. Slit lamp
examination showed improved eyelid hyperemia and PEE OS with the amniotic
membrane ring in place. Successful removal of the ring OS and contact lens OD
was completed in office. The possible need for the use of a second amniotic
membrane OS if central PEE persisted was discussed with the patient. She was
advised to re-initiate all medical therapies: cyclosporine 0.05% ophthalmic solution
BID OU, AS tears 50% every two hours OU, preservative-free artificial tears as
needed OU, and 0.02% hypochlorous acid lid spray QD OU.
FOLLOW UP #3
The patient returned two weeks after removal of the amniotic membrane OS
reporting good compliance with the recommended treatment and continued to
demonstrate overall improvement in comfort and vision OS.
Uncorrected visual acuity remained stable OU. Slit lamp biomicroscopy revealed
stable central PEE OS with trace diffuse injection OU. Due to improvement in
symptoms and decreased inflammation of the ocular surface, the previously ordered
InSight scleral contact lens was applied in office on the left eye. Vision OD was
found to be 20/100 uncorrected with distance pinhole acuity of 20/40+2 and near
acuity of 20/20. The visual acuity OS was 20/30+2 with the scleral lens and a
pinhole acuity OS of 20/25+1 (corrected for monovision with OD for near, OS for
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distance). The lens parameters were 7.0 mm base curve, 15.2 mm diameter, -11.37
D sphere power, and standard peripheral curves. It was ordered with Hydra-PEG®
(Tangible Science; Redwood City, California), a polymer coating that improves
lens surface wettability.8 The lens was determined to be an adequate initial fit with
499 um central fluid reservoir, measured by anterior segment optical coherence
tomography (AS-OCT), adequate limbal clearance and good edge alignment OS.
Application and removal training was successfully completed in office.
The patient was directed to begin daily scleral contact lens wear OS, filling the
contact lens bowl with sodium chloride inhalation solution 0.9% along with
carboxymethylcellulose sodium 1% ophthalmic solution to prevent insertion
bubbles. She was advised to continue using cyclosporine 0.05% ophthalmic
solution BID OU (pre/post scleral lens wear OS), 0.02% hypochlorous acid lid
spray QD OU, and AS tears 50% every two hours OD. She was advised to decrease
AS tears 50% to BID pre/post scleral lens wear OS. Additionally, the use of
preservative-free artificial tears at least QID OS while wearing the scleral contact
lens was recommended.
FOLLOW UP # 4
The patient returned three weeks later for follow-up and reported satisfactory
comfort and vision with scleral lens wear for 10 hours per day OS. She stated good
compliance with proper lens care and medical treatments as directed.
On examination, the uncorrected vision OS was 20/100 with a pinhole acuity of
20/40 and near acuity of 20/20. Corrected vision OS with the scleral lens was
20/40+ and improved to 20/20 with a -1.00 DS over refraction. AS-OCT showed
399 um of central fluid reservoir, adequate limbal clearance, and a well-aligned
edge without impingement after wearing the lens for 6 hours (see Figure 1). Slit
lamp biomicroscopy showed only mild debris in the fluid reservoir. After removal
of the lens, the cornea was assessed OS showing improved trace PEE, greatest in
the interpalpebral zone.
Due to the significant improvement in corneal appearance following scleral lens
wear OS, the patient was advised to continue the current treatment plan. The scleral
lens was re-ordered OS to account for the over refraction (7.0mm base curve, 15.2
diameter, -12.37D power, and Hydra-PEG® coating). The lens was shipped
directly to the patient’s home address.
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Figure 1: AS-OCT of the scleral contact lens OS showing 399 um of apical clearance and
adequate limbal clearance after 6 hours of lens wear.

FOLLOW UP # 5
The patient returned one month after receiving the modified scleral lens with
reports of great vision and comfort with the new scleral contact lens OS.
Uncorrected vision remained stable OD. Corrected distance visual acuity with the
scleral lens OS was 20/20 with a plano sphere over- refraction. After removal of
the lens OS, the cornea was evaluated, and no signs of corneal staining were noted.
This lens was determined to have an ideal fit providing excellent vision and corneal
clarity.
DISCUSSION
KCS, or DES, is a multifactorial disorder, which often presents with irritation,
fluctuation in vision, or irregularities in ocular surface epithelial appearance.9,10
Such changes can significantly impact the ability to perform daily tasks and can be
aggravated by environmental conditions.6 Dry eye syndrome can be categorized
into aqueous deficient dry eye or evaporative dry eye (Sjogren’s vs. non-Sjogren’s).
Evaporative DES occurs due to lipid deficiency within the tear film as a result of
MGD. Aqueous deficient DES, on the other hand, represents a reduced tear volume
in the presence of normal lipid content and evaporation rate.3,10 The most recent
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classification by The Tear Film and Ocular Surface Society’s Dry Eye Workshop
II (TFOS DEWS II) considers KCS a continuum of both categories.3
SS is a chronic, inflammatory autoimmune disease that affects numerous exocrine
glands, in particular the lacrimal gland, and is classified as primary or
secondary.5,6,9,10 Primary SS occurs as an independent disease without concurrent
autoimmune rheumatic disease while secondary SS is associated with another
rheumatic disease such as rheumatoid arthritis or scleroderma.6 This case study
focused on aqueous deficient dry eye, specifically related to secondary Sjogren’s
syndrome as the patient concurrently had a diagnosis of scleroderma. While
systemic scleroderma can cause ocular manifestations including KCS, it is more
likely that this condition caused exacerbation of the patient’s SS leading to the
observed corneal findings and patient symptoms. Scleroderma may cause eyelid
changes such as lagophthalmos and telangiectasia as well as KCS.11 The patient did
not exhibit signs of lagophthalmos, and her telangiectasia was managed
concurrently with her MGD using thermal pulsation treatment and maintenance
hypochlorous acid lid spray. (The authors of this report acknowledge that other
autoimmune conditions can play a role, but chose to focus the discussion on treating
the patient’s ocular manifestations of secondary SS.)
The main lacrimal gland is destroyed in SS via lymphocyte infiltration.6,9 As a
result of this process, the lacrimal gland is unable to produce adequate basal or
reflex tears.12 The aqueous portion of the tears is made up of secretions from the
lacrimal gland primarily, as well as from several accessory glands located within
the conjunctival fornix and tarsal plates (glands of Krause and glands of Wolfring,
respectively).7,10 The accessory lacrimal glands account for roughly 10% of the
total aqueous secretion; however, it remains unclear whether or not these accessory
glands can provide adequate tear volume to prevent KCS.7,13 The importance of
tear components, including epithelial growth factor (EGF) and vitamin A, have
been found to play a vital role in the proliferation, differentiation, and maturation
of epithelial cells across the ocular surface.10 The lack of tear production from the
main lacrimal gland in SS leads to a compromised ocular surface epithelium and
resulting dry eye symptoms.7,9,10,13 An insufficient pre-corneal tear film leads to a
poor refractive surface and resultant blurred vision.10 As demonstrated by this case,
signs and symptoms of dry eye due to SS can be persistent regardless of many
treatment approaches, making management extremely challenging.
DIAGNOSIS
Clinical diagnosis of KCS is often based on a combination of patient symptoms,
ocular signs, and in-office testing. As patient symptoms can be variable, especially
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in the course of SS, clinicians often rely on simple, in-office tests. Such testing can
include Schirmer I/II testing, TBUT, sodium fluorescein staining, and tear
osmolarity.14,15 Schirmer testing is used to quantify tear total secretion and is most
commonly performed without anesthesia providing a measurement of reflex tearing
( Schirmer I). Less frequently, the inclusion of anesthetic can be used to test basal
secretion (Schirmer II).15 As the patient in this case presented with a known
diagnosis of KCS due to secondary SS, repeat Schirmer testing was not considered
essential in the management course by the authors of this report. The TBUT helps
to identify any instability of the tear film and leads to a diagnosis of evaporative
DES.15 However, research has demonstrated no clear difference in TBUT values
between aqueous deficient DES and evaporative DES further solidifying the more
recent continuum of KCS put forth by TFOS DEWS II.3,15,16 The presence or
absence of ocular surface staining can help to gauge the severity of KCS.15 In
addition, it has been shown that patients with SS often have more severe ocular
surface staining as compared to patients without SS.15 For the patient in this case,
corneal staining was utilized as one of the main measures of monitoring for
improvement with introduction of each new treatment. Tear film osmolarity has
been recognized as one of the most reliable indicators of KCS. Osmolarity is
measured with the use of devices such as TearLab (TearLab Corporation; San
Diego, CA), which provides quantifiable data to monitor osmolarity from visit to
visit.1,13,15 The biggest limitation in measuring osmolarity in this patient was the
lack of instrumentation. Finally, post-LASIK dry eye is a well-known condition
which can complicate management of KCS. While not considered essential by the
authors of this report, corneal sensitivity testing may be done for patients with a
history of LASIK.
TREATMENT AND MANAGEMENT
Although the patient had a concurrent diagnosis of MGD, her persistent corneal
findings were more related to aqueous deficient dry eye due to secondary SS and
will be the focus of this discussion. Briefly, her MGD treatments included 0.02%
hypochlorous acid lid spray and Lipiflow® thermal pulsation treatment. For this
patient, many treatments for KCS were found to be unsuccessful long-term. While
initial treatments of cyclosporine 0.05% ophthalmic solution, preservative-free
artificial tears, and 0.02% hypochlorous acid lid spray were found to be somewhat
adequate maintenance therapy, they did not allow for tolerable comfort or lasting
corneal clarity. The patient continued to return with complaints of minimal
improvement in comfort and showed unwavering reduced visual acuity. The
initiation of AS tears 50% allowed the first subjective report of improved comfort.
Drastic improvement in visual acuity was not observed until the placement of an
amniotic membrane rehabilitated the cornea. To maintain the improved ocular
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surface, a scleral lens was introduced. Once a satisfactory lens fit was obtained, the
corneal appearance, as well as visual acuity, was found to remain stable at a
satisfactory level.
TFOS DEWS II proposed a stepwise management plan for treating dry eye
disease.17 This list included all the treatments for our patient. However, it was
acknowledged that the proposed management algorithm does not need to be
followed linearly, due to the varying severity and signs from patient to patient.18
This may make it difficult to determine when to implement each management
option. In the case of this patient, the authors believed that addressing the ocular
inflammation first – with existing prescription topical therapy, and introduction of
AS tears and amniotic membrane placement – helped to facilitate a successful
therapeutic scleral lens fitting necessary to sustain the improved signs and
symptoms.
For the treatment of KCS in patients with SS, AS tears have been found to be
beneficial over the use of artificial tears alone.9 AS tears are made using a variable
combination of the patient’s whole blood diluted in either hyaluronic acid or sterile
saline, and contain nutrients such as Vitamin A and epithelial growth factors, which
are typically found on the ocular surface.9,10 With regular use, AS tears allow these
vital nutrients lost in KCS to be replenished.14 The tear-like biochemical make-up
of AS tears allows for improved viability, proliferation, and migration of the
epithelial cells present on the ocular surface.3 The most common concentration of
serum in AS tears used is 20%, however higher concentrations up to 50% may be
used for more severe cases.9,12 As no preservatives are used in the formulation of
AS tears, it is necessary to store the drops in the refrigerator between uses. Such
precautions can allow for preservation of the tears for up to one month.9,12
The use of human amniotic membrane has been shown to be beneficial as an inoffice treatment of many ocular surface conditions. The main beneficial properties
include acting as a barrier allowing the cornea to heal, reducing friction between
the eyelids and ocular surface, allowing for increased comfort, and promoting
epithelial growth while inhibiting cell death.19 The amniotic membrane is
comprised of three distinct layers: the epithelium, stroma, and basement membrane.
The hyaluronic acid present in the stroma plays an important role of reducing
inflammation by decreasing cytokine expression.14,19 Generally, the membrane will
dissolve over the course of one week with the most common side effects being
blurred vision and mild irritation due to the polycarbonate ring.19 In the case of this
patient, historical use of an amniotic membrane provided initial improvement in
vision and comfort; however, these results were insufficient long-term. The short-
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term benefits of the amniotic membrane were able to be maintained with the
introduction of a scleral lens.
Research has shown the benefits of scleral lens therapy for the management of
severe ocular surface disease, especially in cases when conventional dry eye
treatments have failed.20–22 Scleral lenses are designed to vault the cornea while
maintaining a tear reservoir between the posterior lens surface and the anterior
corneal surface.23,24 This design allows the cornea to be continually bathed with
fluid and shields it from air exposure as well as friction generated by blinking. The
environment set up by the scleral lens allows the corneal epithelium to properly
heal, improving comfort, vision, and symptoms.8 The patient’s scleral lens was
ordered with Hydra-PEG® which is a polymer coating designed to improve lens
wettability, TBUT, deposit resistance, and lubricity.8 Scleral lenses treated with this
coating have been shown to provide superior comfort and improved dry eye
symptoms compared to untreated lenses.8 As seen in this case, it is often beneficial
to combine the use of scleral lenses with other modalities of treatment such as
topical lubricants, AS tears, or cyclosporine. Tear osmolarity is widely accepted as
one of the best markers for KCS.2,3,10,13,24 There has been a strong correlation
documented between tear osmolarity and the severity of KCS.25 One study showed
a statistically significant reduction and maintenance of the tear film osmolarity after
12 months of scleral contact lens wear.24 Although tear osmolarity was not
measured in this case due to unavailable resources, it likely that a reduced
osmolarity would have been observed after 12 months of scleral lens wear.
CONCLUSION
This case illustrates the challenges in the treatment of persistent dry eye disease
due to secondary SS. The lack of basal and reflex tears, due to infiltrative damage
to the lacrimal gland, leads to a damaged ocular surface epithelium and resultant
reduced vision.6,10 The use of AS tears was found to be beneficial in replenishing
the vital growth factors and vitamins normally present in healthy tears allowing for
proper epithelial growth and proliferation.2 Frequent use of AS tears by this patient
provided rapid subjective improvement in ocular comfort and vision. In-office
amniotic membranes have been successfully used in the management of ocular
surface disease. The membrane acts as a platform to allow epithelial regrowth while
halting inflammation.4 The use of an amniotic membrane for this patient allowed
for rapid improvement in the corneal clarity and visual acuity.
While the use of AS tears and amniotic membranes allowed for subjective and
clinical improvement, maintenance of corneal integrity was not successfully
obtained until the introduction of a scleral lens. This patient benefited from the
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unique design of this scleral lens which allowed the corneal surface to be immersed
in an oxygenated solution while being protected from environmental threats. This
environment allowed the corneal epithelium to heal without hindrance from
external forces.7 The combination of AS tears and the use of an amniotic membrane
developed a stable ocular surface, setting the stage for a more ideal scleral contact
lens fit. Regular wear of a scleral lens by this patient resulted in long-term
improvement in clinical appearance of the corneal epithelium as well as stable
visual acuity. This combination treatment modality allowed for the most consistent
visual and physical comfort compared to all other treatments attempted.
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